DDInter1043 DDInter1676
Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Levacetylmethadol {u} (Compound) resembles {v} (Compound) Disopyramide
Levacetylmethadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Levacetylmethadol {u} (Compound) binds {v} (Gene) CYP19A1
Levacetylmethadol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Levacetylmethadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Alvimopan
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Levacetylmethadol {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenoxylate
Levacetylmethadol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Doxylamine
Levacetylmethadol (Compound) resembles Disopyramide (Compound)
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Levacetylmethadol (Compound) binds CYP19A1 (Gene)
Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Levacetylmethadol may lead to a major life threatening interaction when taken with Alvimopan
Levacetylmethadol may lead to a major life threatening interaction when taken with Naltrexone
Levacetylmethadol (Compound) resembles Diphenoxylate (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Levacetylmethadol (Compound) resembles Doxylamine (Compound) and Levacetylmethadol may lead to a major life threatening interaction when taken with Doxylamine